vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and PAMT CORP (PAMT). Click either name above to swap in a different company.
PAMT CORP is the larger business by last-quarter revenue ($141.3M vs $86.8M, roughly 1.6× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -15.1%). PAMT CORP produced more free cash flow last quarter ($-25.0M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -12.0%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
IOVA vs PAMT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $141.3M |
| Net Profit | — | $-29.3M |
| Gross Margin | 67.4% | — |
| Operating Margin | -84.7% | -27.0% |
| Net Margin | — | -20.7% |
| Revenue YoY | 17.7% | -15.1% |
| Net Profit YoY | — | 7.4% |
| EPS (diluted) | — | $-1.38 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $141.3M | ||
| Q3 25 | $67.5M | $150.3M | ||
| Q2 25 | $60.0M | $151.1M | ||
| Q1 25 | $49.3M | $155.3M | ||
| Q4 24 | $73.7M | $166.5M | ||
| Q3 24 | $58.6M | $182.6M | ||
| Q2 24 | $31.1M | $182.9M | ||
| Q1 24 | $715.0K | $182.6M |
| Q4 25 | — | $-29.3M | ||
| Q3 25 | $-91.3M | $-5.6M | ||
| Q2 25 | $-111.7M | $-9.6M | ||
| Q1 25 | $-116.2M | $-8.1M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $-83.5M | $2.4M | ||
| Q2 24 | $-97.1M | $-2.9M | ||
| Q1 24 | $-113.0M | $281.0K |
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -84.7% | -27.0% | ||
| Q3 25 | -140.7% | -3.8% | ||
| Q2 25 | -189.8% | -7.3% | ||
| Q1 25 | -245.8% | -5.9% | ||
| Q4 24 | -117.5% | -22.6% | ||
| Q3 24 | -152.1% | 1.3% | ||
| Q2 24 | -327.6% | -0.4% | ||
| Q1 24 | -16464.6% | -0.4% |
| Q4 25 | — | -20.7% | ||
| Q3 25 | -135.3% | -3.7% | ||
| Q2 25 | -186.2% | -6.4% | ||
| Q1 25 | -235.5% | -5.2% | ||
| Q4 24 | — | -19.0% | ||
| Q3 24 | -142.7% | 1.3% | ||
| Q2 24 | -312.2% | -1.6% | ||
| Q1 24 | -15800.8% | 0.2% |
| Q4 25 | — | $-1.38 | ||
| Q3 25 | — | $-0.27 | ||
| Q2 25 | $-0.33 | $-0.46 | ||
| Q1 25 | $-0.36 | $-0.37 | ||
| Q4 24 | $-0.24 | $-1.44 | ||
| Q3 24 | $-0.28 | $0.11 | ||
| Q2 24 | $-0.34 | $-0.13 | ||
| Q1 24 | $-0.42 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $83.7M |
| Total DebtLower is stronger | — | $333.9M |
| Stockholders' EquityBook value | $698.6M | $210.5M |
| Total Assets | $913.2M | $697.9M |
| Debt / EquityLower = less leverage | — | 1.59× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $83.7M | ||
| Q3 25 | $300.8M | $115.6M | ||
| Q2 25 | $301.2M | $117.3M | ||
| Q1 25 | $359.7M | $102.7M | ||
| Q4 24 | $323.8M | $110.7M | ||
| Q3 24 | $397.5M | $92.3M | ||
| Q2 24 | $412.5M | $114.0M | ||
| Q1 24 | $356.2M | $125.8M |
| Q4 25 | — | $333.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $325.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $698.6M | $210.5M | ||
| Q3 25 | $702.3M | $239.5M | ||
| Q2 25 | $698.5M | $244.9M | ||
| Q1 25 | $767.9M | $269.6M | ||
| Q4 24 | $710.4M | $277.5M | ||
| Q3 24 | $773.5M | $308.9M | ||
| Q2 24 | $768.5M | $306.7M | ||
| Q1 24 | $680.0M | $314.6M |
| Q4 25 | $913.2M | $697.9M | ||
| Q3 25 | $904.9M | $715.2M | ||
| Q2 25 | $907.4M | $707.9M | ||
| Q1 25 | $966.7M | $712.6M | ||
| Q4 24 | $910.4M | $741.7M | ||
| Q3 24 | $991.1M | $756.7M | ||
| Q2 24 | $964.3M | $733.5M | ||
| Q1 24 | $869.8M | $746.4M |
| Q4 25 | — | 1.59× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.17× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $-5.8M |
| Free Cash FlowOCF − Capex | $-61.9M | $-25.0M |
| FCF MarginFCF / Revenue | -71.3% | -17.7% |
| Capex IntensityCapex / Revenue | 10.7% | 13.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $-23.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $-5.8M | ||
| Q3 25 | $-78.7M | $5.9M | ||
| Q2 25 | $-67.4M | $12.2M | ||
| Q1 25 | $-103.7M | $5.0M | ||
| Q4 24 | $-73.3M | $15.2M | ||
| Q3 24 | $-59.0M | $15.5M | ||
| Q2 24 | $-98.4M | $18.7M | ||
| Q1 24 | $-122.3M | $9.6M |
| Q4 25 | $-61.9M | $-25.0M | ||
| Q3 25 | $-89.5M | $2.5M | ||
| Q2 25 | $-74.9M | $5.9M | ||
| Q1 25 | $-109.9M | $-6.8M | ||
| Q4 24 | $-77.5M | $-39.9M | ||
| Q3 24 | $-61.3M | $-33.6M | ||
| Q2 24 | $-98.9M | $4.1M | ||
| Q1 24 | $-126.5M | $-12.2M |
| Q4 25 | -71.3% | -17.7% | ||
| Q3 25 | -132.7% | 1.7% | ||
| Q2 25 | -124.9% | 3.9% | ||
| Q1 25 | -222.8% | -4.4% | ||
| Q4 24 | -105.1% | -24.0% | ||
| Q3 24 | -104.6% | -18.4% | ||
| Q2 24 | -317.9% | 2.2% | ||
| Q1 24 | -17685.3% | -6.7% |
| Q4 25 | 10.7% | 13.6% | ||
| Q3 25 | 16.1% | 2.3% | ||
| Q2 25 | 12.4% | 4.2% | ||
| Q1 25 | 12.6% | 7.6% | ||
| Q4 24 | 5.7% | 33.1% | ||
| Q3 24 | 3.9% | 26.9% | ||
| Q2 24 | 1.4% | 8.0% | ||
| Q1 24 | 583.4% | 12.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 6.44× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 34.11× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
PAMT
| Freight Transportation Service | $123.1M | 87% |
| Fuel Surcharge | $18.2M | 13% |
